Impact of ABO blood group on the prognosis of patients undergoing surgery for esophageal cancer

Wei Wang, Lei Liu, Zhiwei Wang, Min Wei, Qi He, Tianlong Ling, Ziang Cao, Yixin Zhang, Qiang Wang, Minxin Shi, Wei Wang, Lei Liu, Zhiwei Wang, Min Wei, Qi He, Tianlong Ling, Ziang Cao, Yixin Zhang, Qiang Wang, Minxin Shi

Abstract

Background: ABO blood type is an established prognostic factor in several malignancies, but its role in esophageal cancer (EC) is largely unknown. The aim of this study is to determine whether ABO blood group is associated with survival after esophagectomy for EC.

Methods: A total of 406 patients who underwent surgery for EC were enrolled. The associations of ABO blood group with clinical and pathological variables were assessed using chi-square test. Associations of ABO blood group with the survival were estimated using univariable and multivariable Cox proportional hazards regression models.

Results: The ABO blood group proportionally associated with the grade of EC tumor (P = 0.049). The ABO blood group status did not correlate with disease-free survival (DFS) in univariable analysis or multivariable analysis (P > 0.05). And there was no significant relationship between the ABO blood group and overall survival (OS) in univariable analysis or multivariable analysis (P > 0.05).

Conclusions: Our results suggested that no association between ABO blood group and the survival was observed in patients undergoing surgery for EC.

Figures

Fig. 1
Fig. 1
Disease-free survival in 390 patients with esophageal cancer according to ABO blood group. a Survival rates of patients with each blood group. b Survival rates of patients with blood group O compared with patients with non-O (A, B, and AB) blood groups
Fig. 2
Fig. 2
Overall survival in 390 patients with esophageal cancer according to ABO blood group. a Survival rates of patients with each blood group. b Survival rates of patients with blood group O compared with patients with non-O (A, B, and AB) blood groups

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107.
    1. Wang JB, Fan JH, Liang H, Li J, Xiao HJ, Wei WQ, et al. Attributable causes of esophageal cancer incidence and mortality in China. PLoS ONE. 2012;7 doi: 10.1371/journal.pone.0042281.
    1. Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut. 2007;56:1503–11. doi: 10.1136/gut.2006.116665.
    1. Turati F, Edefonti V, Bosetti C, Ferraroni M, Malvezzi M, Franceschi S, et al. Family history of cancer and the risk of cancer: a network of case-control studies. Ann Oncol. 2013;24:2651–6. doi: 10.1093/annonc/mdt280.
    1. O'Doherty MG, Freedman ND, Hollenbeck AR, Schatzkin A, Abnet CC. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut. 2012;61:1261–8. doi: 10.1136/gutjnl-2011-300551.
    1. Gong Y, Yang YS, Zhang XM, Su M, Wang J, Han JD, et al. ABO blood type, diabetes and risk of gastrointestinal cancer in northern China. World J Gastroenterol. 2012;18:563–9. doi: 10.3748/wjg.v18.i6.563.
    1. Wang Z, Liu L, Ji J, Zhang J, Yan M, Liu B, et al. ABO blood group system and gastric cancer: a case-control study and meta-analysis. Int J Mol Sci. 2012;13:13308–21. doi: 10.3390/ijms131013308.
    1. Li Q, Yu CH, Yu JH, Liu L, Xie SS, Li WW, et al. ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. PLoS ONE. 2012;7 doi: 10.1371/journal.pone.0029928.
    1. Wang DS, Chen DL, Ren C, Wang ZQ, Qiu MZ, Luo HY, et al. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer. 2012;131:461–8. doi: 10.1002/ijc.26376.
    1. Poole EM, Gates MA, High BA, Chanock SJ, Cramer DW, Cunningham JM, et al. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control. 2012;23:1805–10. doi: 10.1007/s10552-012-0059-y.
    1. Sheng L, Sun X, Zhang L, Su D. ABO blood group and nasopharyngeal carcinoma risk in a population of Southeast China. Int J Cancer. 2013;133:893–7. doi: 10.1002/ijc.28087.
    1. Qiu MZ, Zhang DS, Ruan DY, Luo HY, Wang ZQ, Zhou ZW, et al. A relationship between ABO blood groups and clinicopathologic characteristics of patients with gastric adenocarcinoma in China. Med Oncol. 2011;28(Suppl 1):S268–73. doi: 10.1007/s12032-010-9735-5.
    1. Wang DS, Wang ZQ, Zhang L, Qiu MZ, Luo HY, Ren C, et al. Are risk factors associated with outcomes in pancreatic cancer? PLoS ONE. 2012;7 doi: 10.1371/journal.pone.0041984.
    1. LH S, MK G, C W. International Union AgainstCancer (UICC):TNM Classification of Malignant Tumours. 7th edition. New York: Wiley-Liss. 2010.
    1. Rahbari NN, Bork U, Hinz U, Leo A, Kirchberg J, Koch M, et al. AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 2012;12:319. doi: 10.1186/1471-2407-12-319.
    1. Ben Q, Wang K, Yuan Y, Li Z. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer. 2011;128:1179–86. doi: 10.1002/ijc.25426.
    1. Klatte T, Xylinas E, Rieken M, Kluth LA, Roupret M, Pycha A, et al. Impact of ABO blood type on outcomes of patients with primary non-muscle-invasive bladder cancer. J Urol 2013.
    1. Kaffenberger SD, Morgan TM, Stratton KL, Boachie AM, Barocas DA, Chang SS, et al. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int. 2012;110:E641–6. doi: 10.1111/j.1464-410X.2012.11366.x.
    1. Yang X, Huang Y, Feng JF. Is there an association between ABO blood group and overall survival in patients with esophageal squamous cell carcinoma? Int J Clin Exp Med. 2014;7:2214–8.
    1. Gates MA, Xu M, Chen WY, Kraft P, Hankinson SE, Wolpin BM. ABO blood group and breast cancer incidence and survival. Int J Cancer. 2012;130:2129–37. doi: 10.1002/ijc.26220.
    1. Yu J, Gao F, Klimberg VS, Margenthaler JA. ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer. Ann Surg Oncol. 2012;19:3159–64. doi: 10.1245/s10434-012-2533-x.
    1. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A, Kaplan B. ABO blood groups are not associated with treatment response and prognosis in patients with local advanced non- small cell lung cancer. Asian Pac J Cancer Prev. 2013;14:3945–8. doi: 10.7314/APJCP.2013.14.6.3945.
    1. Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;345:229–33. doi: 10.1038/345229a0.
    1. Yamamoto F. Cloning the ABH genes. Transfusion. 1990;30:671–2. doi: 10.1046/j.1537-2995.1990.30891020320.x.
    1. Larsen RD, Ernst LK, Nair RP, Lowe JB. Molecular cloning, sequence, and expression of a human GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase cDNA that can form the H blood group antigen. Proc Natl Acad Sci U S A. 1990;87:6674–8. doi: 10.1073/pnas.87.17.6674.
    1. Yazer MH. What a difference 2 nucleotides make: a short review of ABO genetics. Transfus Med Rev. 2005;19:200–9. doi: 10.1016/j.tmrv.2005.02.003.
    1. Kayser K, Hauck E, Andre S, Bovin NV, Kaltner H, Banach L, et al. Expression of endogenous lectins (galectins, receptors for ABH-epitopes) and the MIB-1 antigen in esophageal carcinomas and their syntactic structure analysis in relation to post-surgical tumor stage and lymph node involvement. Anticancer Res. 2001;21:1439–44.
    1. Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clement M. ABH and Lewis histo-blood group antigens in cancer. APMIS. 2001;109:9–31. doi: 10.1111/j.1600-0463.2001.tb00011.x.
    1. Pare G, Chasman DI, Kellogg M, Zee RY, Rifai N, Badola S, et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet. 2008;4 doi: 10.1371/journal.pgen.1000118.
    1. Barbalic M, Dupuis J, Dehghan A, Bis JC, Hoogeveen RC, Schnabel RB, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet. 2010;19:1863–72. doi: 10.1093/hmg/ddq061.
    1. Banks RE, Gearing AJ, Hemingway IK, Norfolk DR, Perren TJ, Selby PJ. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer. 1993;68:122–4. doi: 10.1038/bjc.1993.298.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi